# UBS Asset Management

> UBS Asset Management is a VC fund backing Health Care and Therapeutics. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: London, United Kingdom
- Total investments: 7
- Last investment: Aug 2023
- Lead investor: 14%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/showcase/ubs-asset-management
- Website: https://www.ubs.com/uk/en/asset_management.html

UBS Asset Management is a VC fund in London focused on Health Care and Therapeutics. UBS Asset Management delivers to the UK market the extensive capabilities of a truly global organisation. They offer a powerful partnership of independent global research, state-of-the-art risk management and cost-effective dealing. This all adds up to one clear aim to deliver superior investment performance and client servicing.

## Contacts

5 contacts available for UBS Asset Management. Shizune tracks 4 team members at UBS Asset Management. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/ubs-asset-management?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 29% |
| Therapeutics | 2 | 29% |
| Biotechnology | 2 | 29% |
| Apps | 1 | 14% |
| Medical | 1 | 14% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 29% |
| Series B | 1 | 14% |
| Series C | 1 | 14% |
| Post-IPO Debt | 1 | 14% |
| Private Equity | 1 | 14% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 4 | 57% |
| China | 1 | 14% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Brian Huang | Director (Senior Credit Analyst) | 0 | https://shizune.co/investors/profile/brian-huang-d131 |
| George Manahilov | Managing Director | 1 | https://shizune.co/investors/profile/george-manahilov |
| Ken Geren | manager | 0 | https://shizune.co/investors/profile/ken-geren |
| Thomas Wels | Head of Real Estate & Private Markets | 0 | https://shizune.co/investors/profile/thomas-wels |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| DFD | DFD is a high-tech enterprise engaged in the research, development, production and sales of high-performance inorganic fluorides. | $37.5M | Post-IPO Equity | Aug 17, 2023 |  |
| Nogin | Nogin is an Intelligent Commerce Platform that enables leading brands to keep pace with big retail, drive predictable profitability, and exponential growth, and grow rapidly into the future of commerce. Brands selling direct to consumers (D2C) and through online channel partners can use the Nogin Intelligent Commerce technology, a cloud-basede-commerce environment. Customers of Nogin are free to manage as much or as little of the infrastructure as they see fit while concentrating on their brands. | $60M | Post-IPO Debt | Aug 29, 2022 |  |
| REEF | REEF is North America’s network of mobility and urban logistics hubs with an ecosystem of 4,500 locations and a team of 15,000 associates in 200 cities. Leveraging our proximity to the highly concentrated areas where people live and work, REEF is transforming underutilized urban spaces into neighborhood hubs that serve the needs of cities,residents, and businesses. REEF's technology-driven infrastructure provides congestion-reducing buffering zones and environmentally conscious parking, micro-fulfillment, and delivery solutions to enable the frictionless movement of goods and services.REEF Creates Ecosystems: Each REEF hub is a thriving, connected ecosystem of businesses, cities, and people, enabling the goods and services that keep us moving forward in a sustainable, thoughtful way.REEF Provides Connectivity: REEF hubs enable the last block delivery of products and services to more people, more efficiently than ever before, due to proximity to areas where large numbers of people live and work.REEF Develops Thriving City Hubs: Each REEF hub has been strategically designed to provide buffer zones allowing delivery and rideshare vehicles to use their space, which reduces city traffic and congestion.REEF is launching the next phase of a neighborhood by redefining the possibilities and opportunities of an ecosystem brought to life. | $700M | Private Equity | Nov 03, 2020 |  |
| Harpoon Therapeutics | Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, orantigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer. | $70M | Series C | Nov 12, 2018 |  |
| TCR2 | TCR2 is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to expressdefined TCR alpha/beta chains.TCR2 was founded by Dr. Patrick Baeuerle and MPM Capital. It has scientific operations in Kendall Square, Cambridge, Massachusetts to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world. | $125M | Series B | Mar 21, 2018 |  |
| TCR2 | TCR2 is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to expressdefined TCR alpha/beta chains.TCR2 was founded by Dr. Patrick Baeuerle and MPM Capital. It has scientific operations in Kendall Square, Cambridge, Massachusetts to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world. | $44.5M | Series A | Dec 08, 2016 |  |
| Harpoon Therapeutics | Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, orantigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer. | $15M | Series A | Apr 01, 2016 |  |

7 of 7 investments shown.

## Co-investors
- [MPM Capital](https://shizune.co/investors/profile/mpm-capital) — VC Fund, 4 deals together
- [F2 Ventures](https://shizune.co/investors/profile/f2-ventures) — VC Fund, 2 deals together
- [6 Dimensions Capital](https://shizune.co/investors/profile/6-dimensions-capital) — VC Fund, 1 deal together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 1 deal together
- [Arix Bioscience](https://shizune.co/investors/profile/arix-bioscience) — VC Fund, 1 deal together
- [ArrowMark Partners](https://shizune.co/investors/profile/arrowpoint-partners) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does UBS Asset Management invest in?

UBS Asset Management invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact UBS Asset Management?

Public channels for UBS Asset Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at UBS Asset Management?

The team at UBS Asset Management includes Brian Huang (Director (Senior Credit Analyst)), George Manahilov (Managing Director) and Ken Geren (manager). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co